Forge Therapeutics, Basilea Sign Deal to Pursue New Antibiotics

Forge Therapeutics, founded in 2015 with the goal of developing drugs that target metalloenzymes, said Wednesday it had agreed to let Basilea Pharmaceutica use its chemistry platform to develop new antibiotics. Basilea, a Swiss company, has previously commercialized two drugs, an antifungal, isavuconazole (Cresemba), and an antibiotic, ceftobiprole (Zevtera). The former is marketed and distributed [?]